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Background

Coronavirus disease 2019 (COVID-19) is a manifestation of severe acute respiratory syndrome coronavirus 2, which results in
many different complications including left ventricular (LV) thrombi.

.........................................................................................................................................................................................

Case summary

We present a 30-year-old female presenting with chest pain and shortness of breath. Patient had an extensive history including
heart failure with an ejection fraction 15–20% and COVID-19 2 months ago. Echocardiogram revealed a 3.3 cm × 1.7 cm LV
thrombus which was not present 4 months ago before her diagnosis of COVID-19. The LV thrombus embolized resulting in an
embolus extending from the distal infrarenal abdominal aorta to the common iliac arteries bilaterally. Repeat COVID pre-procedure was positive. She underwent bilateral femoral artery cutdown, bilateral iliac artery embolectomy, superﬁcial femoral artery embolectomy, and bilateral lower extremity fasciotomy. An extensive workup for the aetiology of the LV thrombus turned
out to be negative and COVID-19 was deemed to be the aetiology of the thrombus. The patient was bridged from apixaban to
warfarin and was successfully discharged within a few weeks.

.........................................................................................................................................................................................

Discussion

Hypercoagulability is a known complication of COVID-19 causing thrombi in various parts of the body including the LV. Early
recognition with echocardiography, especially in patients with heart failure, and prompt treatment is key to avoid further complications such as embolization.
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Learning points

•
•
•

Coagulation abnormalities leading to a pro-coagulant state have been noted extensively in literature as one of the manifestations of
Coronavirus disease 2019 (COVID-19), including the formation of left ventricular (LV) thrombus.
Early initiation of anticoagulation in patients with LV thrombus, exacerbated by heart failure, is key to the prevention of further clots.
Patients with LV thrombi must be closely observed for signs and symptoms of embolization of LV thrombus.
Thromboembolism should still be on the differential diagnosis, especially in COVID-19, even if patients are on anticoagulant therapy.
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Introduction

Continued

Since its emergence in late 2019, Coronavirus disease 2019
(COVID-19) has resulted in almost 490 million cases and over 6.1
million deaths worldwide as of April 2022.1 COVID-19 can involve
multiple organs including the respiratory, cardiac, and immune systems.2 The most dreaded complication is acute respiratory distress
syndrome, but it also leads to a hypercoagulable state causing multiple thrombi, including in the left ventricle. We present a case of
left ventricular (LV) thrombus due to COVID-19 infection.

Events

.................................................................................

4 months before
presentation
1 month before
presentation
Initial presentation
Day 1

•
•
•
•
•

Diagnosed with heart failure. Left heart
catheterization revealing normal coronaries
Echo ejection fraction 15–20%, right
ventricular normal size and function. No
left ventricular thrombus
COVID-19: treated with 5 days of
remdesivir
Patient presented with chest pain and
shortness of breath
Transthoracic echocardiogram (TTE)
showing left ventricular ejection fraction
(LVEF) 10–15% and a new 3.3 × 1.7 cm
thrombus in the left ventricular outﬂow
tract at mitral valve base, not present

•
Day 2

•
•

previously
Heparin infusion was started. Apixaban was
discontinued
Patient has absent pulses in lower
extremity bilaterally
Cardiothoracic angiogram aorta with
run-off revealed a near-occlusive embolus
within the distal infrarenal abdominal aorta
extending into the common iliac arteries

•
Day 3

•

bilaterally
She underwent a bilateral femoral artery
cutdown with embolectomy and bilateral
lower extremity fasciotomy
Repeat TTE with original LV thrombus not
being present but showing two new mobile,
echogenic structures in the LV apex and at

Day 5

•

Day 38
Day 40

post-discharge

Timing

•

the basal antero-lateral wall suggestive of
further LV thrombus
Hypercoagulable workup including
antineutrophilic antibodies,
beta-2-glycoprotein, anticardiolipin
antibody was conducted, however, all were
negative
Continued

Events

.................................................................................

2 months

Timeline

4 years before
presentation

Timing

•
•
•

COVID-19 induced hypercoagulability was
deemed the aetiology
Repeat echocardiogram before discharge
—resolution of LV thrombus. LVEF 15%
Patient was discharged on warfarin, after
medical and surgical management/pain
management of bilateral lower extremity
wounds
Repeat TTE showed an LVEF of 25% with
no recurrence of LV thrombus

Case presentation
A 30-year-old female presented with chest pain and shortness of
breath. The patient denies any complaints of palpitations or fevers.
Her medical history was signiﬁcant for non-ischemic cardiomyopathy, diagnosed 4 years ago, requiring an automatic implantable
cardioverter-deﬁbrillator, hypertension, diabetes mellitus, obstructive sleep apnoea, paroxysmal atrial ﬁbrillation on apixaban, and recent COVID-19 infection. Her heart failure had been evaluated by
her primary cardiologist and heart failure doctor by doing a cardiac
catheterization showing normal coronary arteries, ever since her
diagnosis 4 years ago. Previous transthoracic echocardiogram
(TTE) done 4 months prior to admission showed a left ventricular
ejection fraction (LVEF) of 15–20% with Grade 2 diastolic dysfunction and severe global hypokinesis of the LV, along with elevated right
ventricular systolic pressure of 45–50 mmHg. Her medication
history included carvedilol 37.5 mg/day twice a day (b.i.d.), sacubitrilvalsartan 97–103 mg/day b.i.d., spironolactone 25 mg daily, hydralazine 25 mg three times a day (t.i.d.), isosorbide-dinitrate 10 mg
t.i.d., torsemide 20 mg b.i.d., apixaban 5 mg b.i.d., and glipizide 5 mg
b.i.d.. She was admitted to an outside hospital a month prior with
COVID-19, not requiring mechanical ventilation, where she was
treated with remdesivir and dexamethasone, which lead to her recovery, and continued her Eliquis due to normal renal function.
She denies any smoking, or illicit drugs and drinks alcohol socially.
She also has had multiple past admissions for heart failure.
Vital signs showed tachycardia to 117 b.p.m. and elevated blood
pressure at 181/136 mmHg; rest of the vitals including temperature
were within normal limits. Physical examination was signiﬁcant for a
regular, tachycardic pulse but diminished breath sounds at the bases
but no crackles. Cardiovascular examination was unremarkable, including no peripheral signs of endocarditis, including Roth spots,
Osler nodes, Janeway lesions, and splinter haemorrhages. SpO2
was 102 mmHg on arterial blood gas and patient was not requiring
supplemental oxygen.
Initial workup was signiﬁcant for brain natriuretic peptide of
1599 pg/mL (0–99 pg/mL), troponin I high sensitivity of 34 ng/L
(,16ng/L), serum creatinine of 1.15 mg/dL (baseline 0.7 mg/dL)
(0–1.11 mg/dL), D-dimer of 2442 ng/mL (0–230 ng/mL), ferritin
1852 ng/mL (5–204 ng/mL), ﬁbrinogen 925 mg/dL (194–450 mg/
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Figure 1 Transthoracic echocardiogram from 4 months prior to patient current presentation not showing any left ventricular thrombus.

dL), lactate dehydrogenase 1738 U/L (100–220 U/L), WBC 6.1 K/µL
(4.0–12.0 K/µL), and thrombocytopenia at 103 000/mcL (150 000–
400 000/mcL). Electrocardiogram showed sinus tachycardia, tall Pand QRS-waves suggestive of left atrial enlargement (with biﬁd P
waves in lead II with .40 ms between the two peaks) and LV hypertrophy (R wave in aVL . 11 mm). Chest X-ray revealed cardiomegaly and central vascular prominence. A repeat COVID test was
positive. The previous echo from 4 months prior to the current presentation did not show any LV thrombus (Figure 1). TTE during current admission showed decreased LVEF to 10–15%. and a new
mobile mass in the LV outﬂow tract at the base of the mitral valve
which measured 3.3 cm by 1.7 cm suggestive of a thrombus; however, vegetation could not be excluded (Figure 2, Supplemental
data). LV internal dimension in systole and diastole were 7.1 cm
and 7.3 cm, respectively.
The patient was admitted, and a heparin infusion was started for
the LV thrombus. Patient continued to be afebrile and blood cultures
were drawn for concerns for the possibility of endocarditis.
Apixaban was discontinued. Cardiothoracic (CT) surgery was consulted for evaluation for a LV embolectomy; however, medical management was favoured. On Day 2, the patient felt heaviness in her
lower extremities and physical examination revealed absent pulses
bilaterally. Cardiothoracic angiogram aorta with bilateral run-off
(Figure 3) revealed a near-occlusive embolus within the distal infrarenal abdominal aorta extending into the common iliac arteries bilaterally. She underwent a bilateral femoral artery cutdown, bilateral
iliac artery embolectomy, superﬁcial femoral artery embolectomy,
and bilateral lower extremity fasciotomy. A repeat TTE, on Day 3,
did not reveal the original LV thrombus. However, there were two
new mobile, echogenic structures in the LV apex and at the basal
antero-lateral wall suggestive of further LV thrombus.

Figure 2 Apical four-chamber view on echocardiogram showing
a 3.3 × 1.7 cm mobile mass concerning for thrombus during the
current presentation.

To identify the aetiology of the thrombi, a hypercoagulable workup including antinuclear antibodies, beta-2-glycoprotein, and anticardiolipin antibody was conducted; however, all were negative. Blood
cultures that were previously drawn on admission, continued to be
negative for any pathogen making endocarditis and a septic embolus
unlikely. COVID-19 was deemed the aetiology for the LV thrombus.
Heparin was bridged to warfarin. Repeat echocardiogram before discharge did not show any apical thrombus with a LVEF of 15%. After
concerns for surgical wound healing, pain management due to bilateral fasciotomies, successful bridging from heparin to warfarin and
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titration of her heart failure therapy were addressed, the patient was
successfully discharged after 6 weeks. Patient was discharged on carvedilol 25 mg b.i.d., Entresto 49–51 mg b.i.d., spironolactone 25 mg
daily, torsemide 20 mg daily, and warfarin 9 mg daily, until the next
follow-up with her cardiologist. A follow-up echocardiogram, 2

Figure 3 Cardiothoracic angiogram showing a near-occlusive
thrombus within the distal infrarenal abdominal aorta extending
into the common iliac arteries bilaterally.

months later post-discharge, showed an ejection fraction of 25%
with no recurrence of the LV thrombi (Figure 4).

Discussion
The virus SARS-CoV-2 belongs to the coronavirus family, which is
enveloped positive-stranded RNA viruses. This virus is presumed
to act via viral structural spike (S) protein by binding with the
angiotensin-converting enzyme (ACE) II receptor, which is present
in many organs of the body including the pulmonary, cardiac, and
endothelial cells of the blood vessels.2 Of the clinical manifestations
of COVID-19, coagulation abnormalities leading to a hypercoagulable state have been noted extensively in evolving literature. The exact mechanism for the hypercoagulability is not completely
understood. However, in vitro studies of SARS-CoV-1 and data collected regarding COVID-19 suggests that SARS-CoV-2, due to its
near-similarity in its genome with SARS-CoV-1, acts by causing hyperinﬂammation due to increased pro-inﬂammatory cytokines, reducing innate and adaptive responses to the virus, and interfering with
the renin–angiotensin–aldosterone system by decreasing ACE II activity and hence increasing Ang II, resulting in vasoconstriction and
pro-inﬂammatory and pro-oxidative state.3
Endothelial injury is a hallmark of the SARS-CoV-2. Inﬂammatory
cells attached to the endothelial cells of the blood vessels in different
organs including the lungs and heart as well as the elevated levels of
von Willebrand factor and P-selectin, that are released by endothelial
cells when they are compromised, in patients with COVID-19, lead
to hypercoagulability.4 COVID-19 also leads to a hypercoagulable
state by increasing pro-thrombotic factors such as ﬁbrinogen,
D-dimer, Factor VIII, and many others as seen in our patient as

Figure 4 Echocardiogram 2 months post-discharge showing resolution of left ventricular thrombus.
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well.5 Finally, our patient had several risk factors that could lead to
stasis including heart failure.
Left ventricular thrombus is a dreaded complication arising from
cardiac pathologies including myocardial infarction and heart failure.
In a study at Brigham and Women’s Hospital, heart failure was found
to be the main cause of LV thrombi after evaluating over 140 000
echocardiograms.6 One of the many complications of LV thrombus
is embolic events. A cohort study comparing patients with LV thrombus with patients without LV thrombus showed that the former had
four times the long term incidence of embolic events.7
COVID-19 manifests in several haematologic complications including thrombotic complications in the venous system such as
deep venous thrombosis, and the arterial system manifesting as myocardial infarction, stroke, and limb ischaemia.8,9 This patient had a severely depressed ejection fraction that led to stasis and had added
risk factors of being hypercoagulable due to COVID-19, making
her at risk for the formation of a LV thrombus and the subsequent
embolization to the lower limbs.
There have been a few reports of patient developing intracardiac
thrombi in patients with COVID-19.10,11 However, in medical literature, there has not been a reported incident of such LV intracardiac
thrombi, resulting in subsequent embolization into the lower limb
causing ischaemia. Since COVID-19 is a recent entity, there have
been no studies to date regarding the incidence of LV thrombi or
subsequent embolization in patients who have COVID-19.
Due to the lack of randomized trials showing the efﬁcacy of direct
oral anticoagulants (DOACs) in patients with LV thrombi, warfarin is
the mainstay therapy to inhibit clot progression. American Heart
Association guidelines recommend 3–6 months of therapy.12
However, there have been case series and retrospective studies that
have shown increased efﬁcacy of DOACs in the resolution of LV
thrombi13,14 including a quicker resolution of LV thrombi when comparing to warfarin.13 DOACs hold the advantage of having a safer proﬁle in terms of bleeding risk13 and more infrequent monitoring.
Unfractionated heparin (UFH) or low molecular weight heparin
(LMWH) are the most common methods for venous thromboembolism prophylaxis.14 In case of COVID-19, early reports suggest that
UFH and LMWH have antiviral and anti-inﬂammatory properties as
well as antithrombotic activities.15 Treatment failure with apixaban
in our patient can be attributed to many factors, including medication
non-compliance. Another reason for apixaban failure in our patient
could be due to the ability of SARS-CoV-2 to alter the activity of multiple cytochrome P450 enzymes that also play a role in the metabolism
of apixaban. However, the clinical signiﬁcance of these interactions at
this point is unknown. One of the many ways to transition to another
anticoagulation in such patients is to transition to warfarin with parenteral anticoagulation, such as UFH, as bridging therapy.16 As in our patient, a heparin drip was started, and she was transitioned to warfarin.
Echocardiogram done 2 months later after discharge (Figure 4)
showed resolution of the LV thrombus.

Conclusion
Thromboembolism should be considered in the differential diagnosis
of the patients with COVID-19 who develop new vascular or neurological symptoms. Early initiation of anticoagulation is key.
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